Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIALIZE-Outcomes: SZC vs placebo in chronic hemodialysis patients with recurrent hyperkalemia
jRCT2031210105Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Randomised, double-blind trial in hyperkalemia, end-stage kidney disease (ESKD) and arrhythmia comparing SZC arm with Placebo arm (2 arms). Primary endpoint: Primary composite endpoint. Started Jun 2021; status: active, not recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemiaend-stage kidney disease (ESKD)arrhythmia
Beyond the preview
Go deeper on jRCT2031210105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210105.